All In Biotech

Drug Trial Radar · NCT04233437

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Feb 10, 2020

Primary completion

May 16, 2020

Study completion May 16, 2020

Sponsor

Lead sponsor
Moleac Pte Ltd.Industry
Sponsor type
Industry
Collaborators
Moleac Australia Pty Ltd
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-centre phase I study to assess the Drug-Drug Interaction potential of MLC1501 with a cocktail of drugs acting as sensitive clinical probe substrates of Cytochrome P450 isoenzymes and Transporters in healthy subjects . The study will have 2 cohorts, one for the CYP study and the other for the Transporters study. Eligible subjects (n=24) will be assigned to one of the 2 cohorts in a 1:1 ratio.

Conditions

  • Stroke

Interventions

  • MLC1501Drug

    MLC1501 capsules (4 capcules (2000 mg) twice a day)

  • CYP CocktailDrug

    Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg

  • Transporter CocktailDrug

    Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in area under curve (AUC) of individual substrates is being assessed between cocktail alone and cocktail + MLC1501 administrationTime frame: Through study completion, an average of 29 days and 18 days for CYP and Transporter cohort, respectively.
  2. Change in maximum concentration (Cmax) of individual substrates is being assessed between cocktail alone and cocktail + MLC1501 administrationTime frame: Through study completion, an average of 29 days and 18 days for CYP and Transporter cohort, respectively.
  3. Change in time taken to reach maximum concentration (Tmax) of individual substrates is being assessed between cocktail alone and cocktail + MLC1501 administrationTime frame: Through study completion, an average of 29 days and 18 days for CYP and Transporter cohort, respectively.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.